VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a strong financial performance with significant revenue growth and reduced expenses, indicating improved operational efficiency. Despite uncertainties in licensing agreements and future funding, the company has secured substantial nondilutive funding, mitigating immediate financial concerns. The Q&A indicates potential for growth through partnerships and global expansion, though management's lack of specific guidance introduces some uncertainty. Overall, the company's strategic developments and financial improvements suggest a positive outlook for the stock price in the short term.
Key Financial Performance
Revenue for Q4 2025 Year-on-year growth of 133%. Reasons for growth include the first revenue from the CE-marked Nu.Q NETs product in Europe and the first order for Nu.Q Cancer from Lyon for certification in their hospital network.
Revenue for Full Year 2025 $1.7 million, a growth of 40% over the full year 2024. Growth attributed to commercialization efforts, including sales of Nu.Q NETs and Nu.Q Cancer products.
Operating Expenses for Full Year 2025 $4.8 million lower, a reduction of 17% compared to the full year 2024. Reduction due to cost-cutting measures and operational efficiencies.
Net Cash Used in Operating Activities for 2025 $19.7 million, down from $25.9 million in 2024, a 24% reduction. Reduction attributed to cost management and operational efficiencies.
Cash and Cash Equivalents at Year-End 2025 Approximately $1.1 million. Subsequent funding included $5.4 million from an ATM facility and $1.9 million from a convertible note issuance.
Nondilutive Funding Support Approximately $2.3 million received subsequent to year-end, bringing total nondilutive funding from inception to over $25 million. Support from agencies of the Walloon Region in Belgium.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nu.Q Cancer assays: Received first order for clinical certification ahead of routine clinical use in lung cancer.
Nu.Q NETs assay: Included in a $7.3 million government-backed program in France for early detection of sepsis.
Nu.Q Vet Cancer Test: #1 canine cancer screening blood test, now available in over 20 countries. Expanded to feline cancer detection with high accuracy.
Capture-Seq: Developed a method for isolating greater-than-99% pure circulating tumor-derived DNA, showing potential for early-stage cancer detection.
Human licensing strategy: Signed agreements with Werfen and Hologic, both multibillion-dollar companies, to commercialize Nu.Q platform.
Nu.Q Discover: Serving close to 100 clients worldwide, including top pharma and diagnostic companies, accelerating disease research and drug development.
Veterinary market: Expanded Nu.Q Vet Cancer Test to over 20 countries and introduced automation for scaling operations.
Revenue growth: Achieved 40% year-on-year revenue growth in 2025, with $1.7 million in revenue.
Cost reduction: Reduced operating expenses by 17% compared to 2024.
Funding: Secured $5.4 million from ATM facility, $1.9 million from convertible note, and $2.3 million in nondilutive funding from Belgium.
Licensing agreements: Ongoing discussions with 10 leading diagnostic and liquid biopsy companies to secure diverse deal structures.
Reimbursement submission: Preparing reimbursement submission for Nu.Q Cancer in France, aiming for routine clinical use by Q4 2026.
Point-of-care technology: Developing lateral flow test for nucleosome quantification, targeting low-income countries and critical diseases like sepsis.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Volatility: Revenues remain unpredictable and 'lumpy' at this early stage of commercialization, making financial forecasting challenging.
Cash Flow Constraints: Net cash used in operating activities was $19.7 million in 2025, with cash and cash equivalents at year-end totaling only $1.1 million. The company had to rely on additional funding sources, including convertible notes and ATM facilities, to sustain operations.
Regulatory and Reimbursement Challenges: The company is in the process of seeking reimbursement approval for its Nu.Q Cancer assays in France, which is critical for routine clinical use. Delays or denials in reimbursement could impact commercialization timelines.
Market Adoption Risks: The adoption of new diagnostic technologies, such as Nu.Q Cancer and Nu.Q NETs, depends on acceptance by healthcare providers and integration into clinical workflows, which may face resistance or delays.
Competitive Pressures: The company is negotiating licensing agreements with leading diagnostic and liquid biopsy companies, but competition in the liquid biopsy and diagnostic markets is intense, potentially impacting deal terms and market share.
Operational Scaling Risks: The company is focusing on central lab automation to meet increasing demand, but scaling operations to handle higher volumes could pose logistical and operational challenges.
Dependence on Licensing Agreements: The company’s strategy heavily relies on securing licensing agreements with large diagnostic companies. Delays or failures in finalizing these agreements could hinder revenue growth.
Economic and Funding Risks: The company has received significant nondilutive funding from the Walloon Region in Belgium, but future funding uncertainties could impact long-term operations and R&D activities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company anticipates a similar revenue growth trajectory in 2026 as seen in 2025, driven by the commercialization of Nu.Q Discover and other products.
Licensing Agreements: VolitionRx aims to secure a wide range of licensing agreements in the human diagnostic space throughout 2026, with potential for upfront and milestone payments and recurring revenue.
Nu.Q Cancer Assays: The company expects the first clinical use of Nu.Q Cancer assays in routine clinical practice in France by Q4 2026, pending reimbursement approval.
Nu.Q NETs Assay: The Nu.Q NETs assay is included in the DETECSEPS study for early detection of sepsis, with potential to improve hospital efficiency and patient outcomes. The company is also developing a lateral flow test for point-of-care quantification of nucleosomes, with updates expected in the coming months.
Capture-Seq Technology: VolitionRx is actively discussing partnerships with large liquid biopsy and diagnostic companies to accelerate the development and launch of its Capture-Seq technology, which has shown promising results in early-stage cancer detection.
Veterinary Market Expansion: The company plans to expand its Nu.Q Vet Cancer Test offerings, including the introduction of a feline cancer assay, which represents a significant commercial opportunity.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide additional insights into the current state of the liquid biopsy field and the implications of the NHS-Galleri trial's failure?
A:Cameron Reynolds emphasized that while other companies have made efforts, there is still a significant opportunity for a routine, low-cost, and accurate test like theirs. He highlighted their promising early-stage detection capabilities and ongoing collaborations with larger companies. He refrained from criticizing competitors and focused on their unique position in the market.
Q:How do you expect the Nu.Q Cancer assays to ramp up in terms of volume through 2026?
A:Cameron Reynolds deferred to the CFO, who stated that they expect the assays to ramp up quickly once reimbursement is approved, likely by Q4 2026. However, they are not providing specific guidance at this time due to uncertainties.
Q:How many new licensing deals do you expect to close this year?
A:Cameron Reynolds mentioned ongoing discussions with multiple companies and governments, expecting multiple deals across cancer and NETs tests this year. However, he did not provide an exact number.
Q:Can you comment on the rate of acceptance of the vet test for canines among different partners and any commonalities among the more successful ones?
A:Cameron Reynolds noted that centralized lab testing is key to acceptance and growth. He mentioned progress with partners like Fuji and Revvity and highlighted the potential for feline cancer tests to expand the market. However, he acknowledged that growth has been lumpy and unpredictable.
Q:Is the European hospital network model for sepsis and lung cancer a template for global expansion?
A:Cameron Reynolds explained that their strategy involves leveraging partnerships with large companies like Revvity to expand in Europe. He highlighted the French government's interventional study as a significant milestone and a potential model for global expansion.
Q:How amenable is the Capture-Seq process to front-end automation in the lab, and how easily could it be integrated into other tests?
A:Chief Scientist Jacob Micallef stated that the process is highly suitable for automation and integration into other tests. He explained that the process involves a magnetic antibody and sequencing, which are straightforward to automate.
Q:What is the anticipated timing of the feline cancer milestone?
A:CFO Terig Hughes stated that they expect to collect the milestone payment this year, but the exact timing depends on the publication of the related paper.
Q:What is the expected operating expense profile for 2026?
A:CFO Terig Hughes mentioned ongoing cost-saving measures, targeting a 25%-30% reduction in cash operating expenses by the end of the year. He noted that the company is shifting from R&D to commercialization, which will lower costs further.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on the volume ramp-up of Nu.Q Cancer assays through 2026 and the exact number of licensing deals expected this year. Additionally, they did not provide precise details on the timing of the feline cancer milestone or the operating expense profile for 2026, citing uncertainties and ongoing processes.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CTCF DNA
DETECSEPS
DNA blood
DNA plasma
Lung Cancer
Mayo Clinic
NETs NETosis
Professor
Reimbursement
Score
Stage
biopsy manuscript
cancer patient
cat
cell
clinician
colleague
detection
emergency
failure
flow
government
health care
hello
hospital
identification
life
need
potential
sequence
set
setting
severity
support
survival
trauma
treatment decision
tumor DNA
week
year
VNRX Transcript
VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript
Unknown5-15
The earnings call summary shows positive financial metrics such as a 25% revenue increase and improved net loss, gross margin, and cash flow. However, the absence of strategic initiatives, operational updates, and return discussions, coupled with the acknowledgment of risks in forward-looking statements, balances the sentiment. Without additional insights from the Q&A section, the sentiment remains neutral, lacking strong catalysts for significant stock price movement.
VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript
Positive4-1
The earnings call reveals a strong financial performance with significant revenue growth and reduced expenses, indicating improved operational efficiency. Despite uncertainties in licensing agreements and future funding, the company has secured substantial nondilutive funding, mitigating immediate financial concerns. The Q&A indicates potential for growth through partnerships and global expansion, though management's lack of specific guidance introduces some uncertainty. Overall, the company's strategic developments and financial improvements suggest a positive outlook for the stock price in the short term.
VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call reveals mixed signals: strong cost management and significant partnership potential, but unpredictable revenues and no revenue guidance for 2025. The Q&A highlights optimism about partnerships and market expansion, but also notes unclear timelines and revenue breakdowns. These factors suggest limited immediate impact on stock price, leading to a neutral prediction.
VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript
Positive8-15
Despite lacking a market cap, the company shows significant potential with a 44% revenue growth, improved net loss, and ongoing licensing discussions. The Q&A highlights strong interest in the Nu.Q platform, repeat orders, and potential revenue from the Taiwan program. However, the absence of revenue guidance and confidentiality on human deals add uncertainty. Overall, the positive aspects, especially the strong revenue growth and potential new deals, outweigh the negatives, suggesting a positive stock price movement.
VNRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
